InVivo Therapeutics Corpの推定成長EPS Q/Q

InVivo Therapeutics Corpの推定成長EPS Q/Qは何ですか。

InVivo Therapeutics Holdings Corpの推定成長EPS Q/Qは-35.71%です。

推定成長EPS Q/Qの定義は何ですか。



期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

NASDAQのセクタHealth Careにおける推定成長EPS Q/Qの企業と比べるInVivo Therapeutics Corp

InVivo Therapeutics Corpは何をしますか。

about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi

InVivo Therapeutics Corpと類似の推定成長eps q/q